Shares of the two drug makers discussed in today’s article have been beaten down, thanks in large part to an FDA advisory panel vote in one case and disappointing sales of the company’s first drug to earn approval in the other. There is reason to believe, however, that both stocks could bounce back. Are either of these two biotech stocks a buy? CLICK HERE.
Are These 2 Beaten-Down Biotechs Buys Before Bouncing Back?
- by RobH
